Researchers who studied a group of non-dialysis CKD patients found that about one quarter of them suffered from iron deficiency anemia.
Hemoglobin (Hb) levels in non-dialysis CKD patients treated with erythropoiesis-stimulating agents (ESAs) have been on the decline.
Anemic pre-dialysis CKD patients who were switched from darbepoetin to epoetin alfa (EPO) maintained similar hemoglobin levels but at a lower cost, according to a study presented at the National Kidney Foundation’s 2010 Spring Clinical Meetings.
Variant hemoglobin phenotypes, including sickle cell trait and hemoglobin C trait, may be associated with resistance to treatment with erythropoietin-stimulating agents (ESAs) among African Americans with end-stage renal disease (ESRD).
Hemodialysis (HD) patients hospitalized for infections receive significantly higher amounts of replacement IV iron therapy and cumulative iron dose, according to findings presented here at the National Kidney Foundation 2010 Spring Clinical Meetings.
Please login or register first to view this content.